Anal cancer

Last updated
Anal cancer
Diagram showing stage 1 anal cancer CRUK 189.svg
Diagram showing stage 1 anal cancer
Specialty Oncology
Symptoms Anal bleeding or lump [1]
Usual onsetAge over 45 years [2]
Types Squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma [3]
Risk factors Human papillomavirus (HPV), HIV/AIDS, receptive anal sex, smoking, many sexual partners [1] [4]
Diagnostic method Physical examination, tissue biopsy [1]
Differential diagnosis Anal warts, hemorrhoids, anal fissure [5]
Prevention HPV vaccination, avoiding risk factors [6]
Treatment Radiation therapy, chemotherapy, surgery [1]
Prognosis Five year survival ~68% (US 2015) [2]
Frequency8,300 (US 2019) [2]
Deaths1,280 (US 2019) [2]

Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract. [1] Symptoms may include bleeding from the anus or a lump near the anus. [1] Other symptoms may include pain, itchiness, or discharge from the anus. [1] A change in bowel movements may also occur. [1]

Contents

Risk factors include human papillomavirus (HPV), HIV/AIDS, receptive anal sex, [4] smoking, and many sexual partners. [1] Anal cancer is typically a squamous cell carcinoma. [3] Other types include adenocarcinoma, small cell carcinoma, and melanoma. [3] Diagnosis is suspected based on physical examination and confirmed by tissue biopsy. [1]

Prevention includes avoiding risk factors and HPV vaccination. [6] Standard treatment may include radiation therapy, chemotherapy, and surgery. [1] About 8,300 people are diagnosed a year in the United States, representing about 0.5% of new cancers. [2] Onset is typically after the age of 45. [2] Women are affected more often than men. [2] The number of cases has increased since the 1990s. [3] The five-year survival rate in the United States is 68%. [2]

Signs and symptoms

A squamous cell carcinoma of the anus visible Squamous cell carcinoma of anal rim 01.jpg
A squamous cell carcinoma of the anus visible

Symptoms of anal cancer can include pain or pressure in the anus or rectum, a change in bowel habits, a lump near the anus, rectal bleeding, itching or discharge. Bleeding may be severe. [7] [8]

Risk factors

Pathology

Most anal cancers are squamous cell carcinomas (epidermoid carcinomas), that arises near the squamocolumnar junction. It may be keratinizing (basaloid) or non-keratinizing (cloacogenic). [17]

Other types of anal cancer are adenocarcinoma, lymphoma, sarcoma or melanoma.

Staging

Pathologic TNM staging of anal carcinomas: [18] [19]

Primary tumor (pT)

Regional lymph nodes (pN)

Distant metastasis (pM)

Prevention

Since many, if not most, anal cancers derive from HPV infections, and since the HPV vaccine before exposure to HPV prevents infection by some strains of the virus and has been shown to reduce the incidence of potentially precancerous lesions, [20] scientists surmise that HPV vaccination may reduce the incidence of anal cancer. [21] The efficacy of the vaccine against HPV types 16 and 18 in naive women ≤26 years old has been shown to be between 91-100% but is lower when individuals are vaccinated irrespective of baseline HPV infection at 76%. [22]

In 2010, Gardasil was approved in the US to prevent anal cancer and pre-cancerous lesions in males and females aged 9 to 26 years. The vaccine has been used before to help prevent cervical, vulvar, and vaginal cancer, and associated lesions caused by HPV types 6, 11, 16, and 18 in women. [23]

Screening

As the incidence of anal cancer has increased in recent years, screening and early detection of anal intraepithelial neoplasia (AIN) has become a necessity in patients at risk. This screening detects premalignant lesions, which are highly prevalents, and improves the staging of lesions after treatment. [24]

Anal Pap smears similar to those used in cervical cancer screening have been studied for early detection of anal cancer in high-risk individuals. [25] In 2011, an HIV clinic implemented a program to enhance access to anal cancer screening for HIV-positive men. Nurse practitioners perform anal Papanicolaou screening, and men with abnormal results receive further evaluation with high-resolution anoscopy. The program has helped identify many precancerous growths, allowing them to be safely removed. [26] A similar study was performed in women with a history of cervical cancer or high-grade cervical intraepithelial neoplasia. More than 30% had abnormal anal Pap smears and one third of those already had anal intraepithelial neoplasia. [27]

Treatment

Localised disease

Localised disease (carcinoma-in-situ) and the precursor condition, anal intraepithelial neoplasia (anal dysplasia or AIN) can be ablated with minimally invasive methods such as infrared photocoagulation. [28]

Previously, anal cancer was treated with surgery, and in early-stage disease (i.e., localised cancer of the anus without metastasis to the inguinal lymph nodes), surgery is often curative. The difficulty with surgery has been the necessity of removing the internal and external anal sphincter, with concomitant fecal incontinence. For this reason, many patients with anal cancer have required permanent colostomies. [17]

Current gold-standard therapy is the combination of chemotherapy and radiation treatment to reduce the necessity of debilitating surgery. [29] This "combined modality" approach has led to the increased preservation of an intact anal sphincter, and therefore improved quality of life after definitive treatment. Survival and cure rates are excellent, and many patients are left with a functional sphincter. Some patients have fecal incontinence after combined chemotherapy and radiation. Biopsies to document disease regression after chemotherapy and radiation were commonly advised, but are not as frequent any longer. Current chemotherapy consists of continuous infusion 5-FU over four days with bolus mitomycin given concurrently with radiation. 5-FU and cisplatin are recommended for metastatic anal cancer. [30]

Metastatic or recurrent disease

10 to 20% of patients treated for anal cancer will develop distant metastatic disease following treatment. [31] Metastatic or recurrent anal cancer is difficult to treat, and usually requires chemotherapy. Radiation is also employed to palliate specific locations of disease that may be causing symptoms. Chemotherapy commonly used is similar to other squamous cell epithelial neoplasms, such as platinum analogues, anthracyclines such as doxorubicin, and antimetabolites such as 5-FU and capecitabine. JD Hainsworth developed a protocol that includes Taxol and Carboplatinum along with 5-FU. [32]

Prognosis

Median survival rates for people with distant metastases range from 8 to 34 months. [31] Surgical resection with permanent colostomies was the standard treatment until the 1970s, yielding 5-year overall survival of approximately 50%. The best overall survival rates are seen after combined radiation therapy combined with chemotherapy (5-FU + Mitomycin) in people with T2N0 and T3N0 categories of disease (5-y overall survival: 82%). The 5-year overall survival rates of patients with T4 with no involved lymph nodes, T3 with involved lymph nodes, and T4 with involved lymph nodes disease after the combined treatment is 57%, 57%, and 42%, respectively. [33] [34]

Epidemiology

Worldwide in 2002 there were an estimated 30,400 new cases of anal cancer. [11] With approximately equal fractions in the developing (15,900) and developed (14,500) countries. [11] An estimated 90% (27,400) were attributable to human papillomavirus (HPV). [11]

United States

In 2014 about 7,060 new cases of anal cancer were diagnosed in the United States (4,430 in women and 2,630 in men). [35] It is typically found in adults, average age early 60s. [35] In 2019, an estimated 8,300 adults will be diagnosed with anal cancer. [36]

In the United States, an estimated 800 to 900 people die of anal cancer annually. [35]

United Kingdom

Anal cancer accounts for less than 1% of all cancer cases and deaths in the United Kingdom. Around 1,200 people were diagnosed with the disease in 2011, and around 310 people died in 2012. [37]

Related Research Articles

<span class="mw-page-title-main">Cervical cancer</span> Cancer arising from the cervix

Cervical cancer is a cancer arising from the cervix or in the any layer of the wall of the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.

<span class="mw-page-title-main">Human papillomavirus infection</span> Human disease

Human papillomavirus infection is caused by a DNA virus from the Papillomaviridae family. Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. In some cases, an HPV infection persists and results in either warts or precancerous lesions. These lesions, depending on the site affected, increase the risk of cancer of the cervix, vulva, vagina, penis, anus, mouth, tonsils, or throat. Nearly all cervical cancer is due to HPV, and two strains – HPV16 and HPV18 – account for 70% of all cases. HPV16 is responsible for almost 90% of HPV-positive oropharyngeal cancers. Between 60% and 90% of the other cancers listed above are also linked to HPV. HPV6 and HPV11 are common causes of genital warts and laryngeal papillomatosis.

Penile cancer, or penile carcinoma, is a cancer that develops in the skin or tissues of the penis. Symptoms may include abnormal growth, an ulcer or sore on the skin of the penis, and bleeding or foul smelling discharge.

<span class="mw-page-title-main">Oral cancer</span> Cancer of the lining of the lips, mouth, or upper throat

Oral cancer, also known as mouth cancer, is a cancer of the lining of the lips, mouth, or upper throat. In the mouth, it most commonly starts as a painless white patch, that thickens, develops red patches, an ulcer, and continues to grow. When on the lips, it commonly looks like a persistent crusting ulcer that does not heal, and slowly grows. Other symptoms may include difficult or painful swallowing, new lumps or bumps in the neck, a swelling in the mouth, or a feeling of numbness in the mouth or lips.

<span class="mw-page-title-main">Head and neck cancer</span> Cancer arises in the head or neck region

Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses, or skin of the face. The most common types of head and neck cancer occur in the lips, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the neck or oral cavity. Given the location of these cancers, it is possible for an afflicted individual to experience difficulty breathing.

<span class="mw-page-title-main">Cervical intraepithelial neoplasia</span> Medical condition

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is the abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer. More specifically, CIN refers to the potentially precancerous transformation of cells of the cervix.

<span class="mw-page-title-main">Gardasil</span> Human papillomavirus vaccine

Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). It was developed by Merck & Co. High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. The HPV strains that Gardasil protects against are sexually transmitted, specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. HPV type 16 is responsible for almost 90% of HPV-positive oropharyngeal cancers, and the prevalence is higher in males than females. Though Gardasil does not treat existing infection, vaccination is still recommended for HPV-positive individuals, as it may protect against one or more different strains of the disease.

<span class="mw-page-title-main">Vulvar cancer</span> Cancer involving the vulva

Vulvar cancer is a cancer of the vulva, the outer portion of the female genitals. It most commonly affects the labia majora. Less often, the labia minora, clitoris, or Bartholin's glands are affected. Symptoms include a lump, itchiness, changes in the skin, or bleeding from the vulva.

<span class="mw-page-title-main">Vulvar intraepithelial neoplasia</span> Medical condition

Vulvar intraepithelial neoplasia (VIN) refers to particular changes that can occur in the skin that covers the vulva. VIN is an intraepithelial neoplasia, and can disappear without treatment. VINs are benign but if the changes become more severe, there is a chance of cancer developing after many years, and so it is referred to as a precancerous condition.

<span class="mw-page-title-main">Nasopharyngeal carcinoma</span> Type of throat cancer; most common to occur in the nasopharynx

Nasopharyngeal carcinoma (NPC), or nasopharynx cancer, is the most common cancer originating in the nasopharynx, most commonly in the postero-lateral nasopharynx or pharyngeal recess, accounting for 50% of cases. NPC occurs in children and adults. NPC differs significantly from other cancers of the head and neck in its occurrence, causes, clinical behavior, and treatment. It is vastly more common in certain regions of East Asia and Africa than elsewhere, with viral, dietary and genetic factors implicated in its causation. It is most common in males. It is a squamous cell carcinoma of an undifferentiated type. Squamous epithelial cells are a flat type of cell found in the skin and the membranes that line some body cavities. Undifferentiated cells are cells that do not have their mature features or functions.

Vaginal cancer is an extraordinarily rare form of cancer that develops in the tissue of the vagina. Primary vaginal cancer originates from the vaginal tissue – most frequently squamous cell carcinoma, but primary vaginal adenocarcinoma, sarcoma, and melanoma have also been reported – while secondary vaginal cancer involves the metastasis of a cancer that originated in a different part of the body. Secondary vaginal cancer is more common. Signs of vaginal cancer may include abnormal vaginal bleeding, dysuria, tenesmus, or pelvic pain, though as many as 20% of women diagnosed with vaginal cancer are asymptomatic at the time of diagnosis. Vaginal cancer occurs more frequently in women over age 50, and the mean age of diagnosis of vaginal cancer is 60 years. It often can be cured if found and treated in early stages. Surgery alone or surgery combined with pelvic radiation is typically used to treat vaginal cancer.

HspE7 is an investigational therapeutic vaccine candidate being developed by Nventa Biopharmaceuticals for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV). HspE7 uses recombinant DNA technology to covalently fuse a heat shock protein (Hsp) to a target antigen, thereby stimulating cellular immune system responses to specific diseases. HspE7 is a patented construct consisting of the HPV Type 16 E7 protein and heat shock protein 65 (Hsp65) and is currently the only candidate using Hsp technology to target the over 20 million Americans already infected with HPV.

An anal Pap smear is the anal counterpart of the cervical Pap smear. It is used for the early detection of anal cancer. Some types of human papillomavirus (HPV) can cause anal cancer. Other HPV types cause anogenital warts. Cigarette smokers, men who have sex with men, individuals with a history of immunosuppression and women with a history of cervical, vaginal and vulval cancer are at increased risk of getting anal cancer. Vaccination against HPV before initial sexual exposure can reduce the risk of anal cancer.

Anal dysplasia is a pre-cancerous condition which occurs when the lining of the anal canal undergoes abnormal changes. It can be classified as low grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). Most cases are not associated with symptoms, but people may notice lumps in and around the anus.

<span class="mw-page-title-main">Oropharyngeal cancer</span> Pharynx cancer that is located in the oropharynx

Oropharyngeal cancer, also known as oropharyngeal squamous cell carcinoma and tonsil cancer, is a disease in which abnormal cells with the potential to both grow locally and spread to other parts of the body are found in the oral cavity, in the tissue of the part of the throat (oropharynx) that includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx.

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

Neuroendocrine carcinoma of the cervix is best defined separately:Neuroendocrine: Of, relating to, or involving the interaction between the nervous system and the hormones of the endocrine glands.Carcinoma: An invasive malignant tumor derived from epithelial tissue that tends to metastasize to other areas of the body.

<span class="mw-page-title-main">Cervical cancer staging</span> Medical condition

Cervical cancer staging is the assessment of cervical cancer to determine the extent of the spread of cancer beyond the cervix. This is important for determining how serious the cancer is and to create the best treatment plan.

Conjunctival squamous cell carcinoma and corneal intraepithelial neoplasia comprise ocular surface squamous neoplasia (OSSN). SCC is the most common malignancy of the conjunctiva in the US, with a yearly incidence of 1–2.8 per 100,000. Risk factors for the disease are exposure to sun, exposure to UVB, and light-colored skin. Other risk factors include radiation, smoking, HPV, arsenic, and exposure to polycyclic hydrocarbons.

Carcinoma of the tonsil is a type of squamous cell carcinoma. The tonsil is the most common site of squamous cell carcinoma in the oropharynx. It comprises 23.1% of all malignancies of the oropharynx. The tumors frequently present at advanced stages, and around 70% of patients present with metastasis to the cervical lymph nodes. . The most reported complaints include sore throat, otalgia or dysphagia. Some patients may complain of feeling the presence of a lump in the throat. Approximately 20% patients present with a node in the neck as the only symptom.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 "Anal Cancer Treatment". National Cancer Institute. 2018. Retrieved 30 May 2019.
  2. 1 2 3 4 5 6 7 8 "Cancer of the Anus, Anal Canal, and Anorectum—Cancer Stat Facts". SEER. Retrieved 30 May 2019.
  3. 1 2 3 4 Nelson, VM; Benson AB, 3rd (January 2017). "Epidemiology of Anal Canal Cancer". Surgical Oncology Clinics of North America. 26 (1): 9–15. doi:10.1016/j.soc.2016.07.001. PMID   27889039.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  4. 1 2 Daling, Janet; et al. (1987). "Sexual Practices, Sexually Transmitted Diseases, and the Incidence of Anal Cancer". The New England Journal of Medicine. 317 (16): 973–977. doi:10.1056/NEJM198710153171601. PMID   2821396.
  5. ↑ Garden, O. James; Bradbury, Andrew W.; Forsythe, John L. R.; Parks, Rowan W. (2012). Principles and Practice of Surgery E-Book. Elsevier Health Sciences. p. 272. ISBN   9780702051166.
  6. 1 2 "Anal Cancer Prevention". National Cancer Institute. 14 February 2014. Retrieved 30 May 2019.
  7. ↑ National Cancer Institute. Anal Cancer Treatment (PDQ) Patient Version. Archived July 14, 2009, at the Wayback Machine 13 June 2008. Accessed 26 June 2009.
  8. ↑ Stanley, Margaret A; Winder, David M; Sterling, Jane C; Goon, Peter KC (2012). "HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues". BMC Cancer. 12 (1): 398. doi: 10.1186/1471-2407-12-398 . ISSN   1471-2407. PMC   3488563 . PMID   22958276.
  9. ↑ Frisch M (August 2002). "On the etiology of anal squamous carcinoma". Danish Medical Bulletin. 49 (3): 194–209. PMID   12238281.
  10. ↑ Frisch M, Glimelius B, van den Brule AJ, et al. (November 1997). "Sexually transmitted infection as a cause of anal cancer". N. Engl. J. Med. 337 (19): 1350–58. doi: 10.1056/NEJM199711063371904 . PMID   9358129.
  11. 1 2 3 4 Parkin DM (2006). "The global health burden of infection-associated cancers in the year 2002". Int. J. Cancer. 118 (12): 3030–44. doi: 10.1002/ijc.21731 . PMID   16404738. S2CID   10042384.
  12. 1 2 "Fred Hutchinson Cancer Research Center, Changing Trends in Sexual Behavior May Explain Rising Incidence of Anal Cancer Among American Men and Women". Fred Hutchinson Cancer Research Center (fhcrc.org). 2004-07-06. Retrieved 2010-04-21.
  13. ↑ "STD Facts – HPV and Men". Archived from the original on 14 September 2007. Retrieved 2007-08-17.
  14. 1 2 3 "Anal Cancer". American Cancer Society. Archived from the original on 2014-12-22. Retrieved 2014-12-22.
  15. ↑ Saleem AM, Paulus JK, Shapter AP, Baxter NN, Roberts PL, Ricciardi R (2011). "Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm". Obstetrics and Gynecology. 117 (3): 643–49. doi:10.1097/AOG.0b013e31820bfb16. PMID   21343768. S2CID   43339714.
  16. ↑ Sink JD, Kramer SA, Copeland DD, Seigler HF (1978). "Cloacogenic carcinoma". Annals of Surgery. 188 (1): 53–59. doi:10.1097/00000658-197807000-00009. PMC   1396653 . PMID   666378.
  17. 1 2 "Anal Cancer". The Lecturio Medical Concept Library. Retrieved 28 June 2021.
  18. ↑ American Joint Committee on Cancer, AJCC Cancer Staging Form Supplement, AJCC Cancer Staging Manual, Eighth Edition, Last updated 05 June 2018.
  19. ↑ MB Amin, SB Edge, FL Greene, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
  20. ↑ ""Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study: Pivotal Study Evaluating Efficacy of Gardasil in Males in Preventing HPV 6, 11, 16 and 18-Related External Genital Lesions"". Merck Research and Development News. (www.merck.com). Archived from the original on 15 December 2008. Retrieved 2008-11-15.
  21. ↑ Tuller, David (2007-01-31). "HPV vaccine may help to prevent anal cancer". International Herald Tribune. Retrieved 2014-12-22.
  22. ↑ Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines. 2021;9(12).
  23. ↑ US approves anal cancer vaccine http://www.channelnewsasia.com/stories/health/view/1100843/1/.html Archived 2011-01-01 at the Wayback Machine
  24. ↑ Fernández Isart, Myriam; Serra Esteban, Julia; Segura Sampedro, Juan José; Amengual Antich, Isabel; Martínez Ortega, Marco Antonio; Forteza Valades, Ana; Riera Jaume, Melchor; González Argente, Francesc Xavier (2022-03-14). "Anal intraepithelial neoplasia screening in patients with human immunodeficiency virus infection". Revista Espanola de Enfermedades Digestivas. 114 (12): 713–718. doi: 10.17235/reed.2022.8489/2021 . ISSN   1130-0108. PMID   35285660. S2CID   247341037.
  25. ↑ Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H (2006). "Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review". Clin. Infect. Dis. 43 (2): 223–33. doi:10.1086/505219. PMID   16779751. S2CID   8447335.
  26. ↑ "Hospital HIV Clinic Offers Convenient, Proactive Screening for Anal Cancer, Enabling Identification and Treatment of Precancerous Lesions". Agency for Healthcare Research and Quality. 2013-04-10. Retrieved 2013-05-10.
  27. ↑ Wohlmuth, Christoph; Ghorab, Zeina; Shier, Michael; Tinmouth, Jill; Salit, Irving E.; Covens, Allan; Zhang, Liying; Vicus, Danielle (2020-10-01). "Cytology-based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer". Cancer Cytopathology. 129 (2): 140–147. doi: 10.1002/cncy.22360 . ISSN   1934-6638. PMID   33002327. S2CID   222168316.
  28. ↑ Goldstone SE, Kawalek AZ, Huyett JW (2005). "Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions". Diseases of the Colon and Rectum. 48 (5): 1042–54. doi:10.1007/s10350-004-0889-0. PMID   15868241. S2CID   25694842.
  29. ↑ National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. V 1.2013" (PDF).
  30. ↑ Ghosn M, Kourie HR, Abdayem P, Antoun J, Nasr D (2015). "Anal cancer treatment: current status and future perspectives". World J. Gastroenterol. 21 (8): 2294–302. doi: 10.3748/wjg.v21.i8.2294 . PMC   4342904 . PMID   25741135.
  31. 1 2 Dewdney A, Rao S (2012). "Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm?". ISRN Oncology. 2012: 1–6. doi: 10.5402/2012/756591 . PMC   3352602 . PMID   22619735.
  32. ↑ "Fluorouracil". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  33. ↑ Gunderson et al., Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US Gastrointestinal Intergroup RTOG 98-11 Phase 3 Trial. Int J Radiation Oncol Biol Phys, 2013, Vol. 87, No. 4, pp. 638–645.
  34. ↑ Suzanne Russo, et al., Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):591–605
  35. 1 2 3 "Detailed Guide: Anal Cancer What Are the Key Statistics About Anal Cancer?". Archived from the original on 2016-12-03. Retrieved 2008-11-18.
  36. ↑ "Anal Cancer: Statistics". Cancer.net. 25 June 2012. Retrieved November 20, 2019.
  37. ↑ "Anal Cancer Statistics". Cancer Research UK. Retrieved 27 October 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.